Versant Capital Management Inc Buys 93 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Versant Capital Management Inc lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 46.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 295 shares of the medical research company’s stock after acquiring an additional 93 shares during the period. Versant Capital Management Inc’s holdings in IQVIA were worth $58,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. Capital Performance Advisors LLP bought a new position in shares of IQVIA in the third quarter valued at approximately $27,000. Park Place Capital Corp bought a new position in IQVIA in the 3rd quarter worth $28,000. Itau Unibanco Holding S.A. acquired a new position in IQVIA during the 2nd quarter worth $29,000. Avior Wealth Management LLC grew its position in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Finally, Assetmark Inc. increased its stake in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have issued reports on IQV shares. The Goldman Sachs Group lowered their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Wednesday, December 11th. Evercore ISI cut their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Finally, Robert W. Baird cut their price objective on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $255.82.

IQVIA Price Performance

Shares of IQVIA stock opened at $197.39 on Monday. The stock has a market capitalization of $35.83 billion, a price-to-earnings ratio of 25.90, a P/E/G ratio of 2.05 and a beta of 1.49. The firm’s 50-day moving average price is $202.86 and its two-hundred day moving average price is $222.07. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.